Sanofi Sees Price Pressure for Diabetes Treatment

The video discusses sector earnings from Novartis and Sanofi, focusing on Sanofi's CEO and board dynamics, market performance, and strategic challenges. It highlights concerns about the diabetes market, particularly pricing pressures in the US. Novartis's earnings and the sustainability of cost reductions are also examined.

What was the market's reaction to the company's recent earnings results?

What challenges does the company face with its diabetes franchise moving forward?